- Stocks
- Pharma & Healthcare
- Vasundhara Ras
Vasundhara Ras share price
NSE: VRLPharma & HealthcareChemicals
Vasundhara Ras at a glance
With a market capitalisation of ₹53 Cr, it ranks 3040th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Chemicals.
In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹12 Cr (+53.2% year on year) and net profit ₹2 Cr (+451.1%), on a standalone basis. Promoters held 61.98% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹53 CrRank 3040 on NSE
- EPS (TTM)
- ₹18.34to Q4 FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Vasundhara Ras quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹7 Cr | ₹12 Cr |
| Revenue YoY | −8.4% | +4.9% | +7.2% | −30.3% | −0.9% | −9.8% | −15.5% | +53.2% |
| Net profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr |
| Net profit YoY | −10.4% | +5.8% | +5.1% | −78.9% | −33.7% | +40.1% | −50.3% | +451.1% |
| Net margin | 11.3% | 15.0% | 16.4% | 5.8% | 7.5% | 23.4% | 9.7% | 20.9% |
| EPS | ₹2.71 | ₹4.61 | ₹4.57 | ₹1.43 | ₹1.80 | ₹6.47 | ₹2.27 | ₹7.80 |
Vasundhara Ras shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 61.98% | 61.98% | 61.98% | 61.98% | 61.98% | 61.98% |
| Non-institutions | 38.02% | 38.02% | 38.02% | 38.02% | 38.02% | 38.02% |
Vasundhara Ras vs peers
The listed Pharma & Healthcare companies nearest to Vasundhara Ras by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| CONSTRONICConstronics Inf | — | — | — | ₹57 Cr | — | — |
| KABRADGKabra Drugs | — | — | — | ₹56 Cr | — | — |
| BANDARAMBandaram Pharma | — | — | — | ₹53 Cr | — | — |
| VRLVasundhara Ras | — | — | — | ₹53 Cr | — | — |
| VIVIMEDLABVivimed Labs | ₹6.21 | −1.90% | −45.8% | ₹51 Cr | — | — |
| SHREEPACShree Pacetroni | — | — | — | ₹50 Cr | — | — |
| BIOFILCHEMBiofil Chemicals & Pharmaceuticals | ₹30.00 | +2.15% | −27.3% | ₹49 Cr | 17.5 | — |
Ask anything about Vasundhara Ras
Pivot answers on the live chart with evidence you can check, and tests strategies against VRL's own history. Try: “Why has VRL moved over the last three months?” · “Backtest a 50-day moving-average crossover on VRL over five years” · “Compare VRL with CONSTRONIC on margins and valuation”
Frequently asked questions about Vasundhara Ras
What is the market cap of Vasundhara Ras?
Vasundhara Ras' market capitalisation is ₹53 Cr (₹53 Cr) at the 22 Oct 2026 close, ranking 3040th among the NSE companies Pivot tracks.
What were Vasundhara Ras' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Vasundhara Ras reported revenue of ₹12 Cr, +53.2% year on year, and net profit of ₹2 Cr, +451.1% year on year.
What is the shareholding pattern of Vasundhara Ras?
As of 30 Jun 2026: promoters 61.98%, non-institutions 38.02%.
Who are Vasundhara Ras' competitors?
The listed Pharma & Healthcare companies closest to Vasundhara Ras by market cap are Constronics Inf, Kabra Drugs, Bandaram Pharma, Vivimed Labs, Shree Pacetroni and Biofil Chemicals & Pharmaceuticals.
Is Vasundhara Ras a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Vasundhara Ras' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VRL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text